A Firefly is lighting up operating rooms, making it easier for robotic surgeons to remove tumors. However, this Firefly is not the type that children catch in a jar during warm summer evenings. Instead, it’s a technology that uses a wavelength of light not visible to the human eye. A special dye is then injected which causes a bright green fluorescence of certain tissues, hence the name “Firefly.” This green glow lets surgeons clearly see the difference between cancerous and healthy tissue when performing surgery, allowing them to remove the tumor while saving the rest of the healthy organ.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7342452-firefly-lighting-operating-rooms/
Every organ donor has the potential to save eight lives, which is the foundation of the new public awareness campaign from the Center for Organ Recovery & Education (CORE). Using multiple channels such as outdoor, television, print and radio advertising, transit wraps, a brand new website and social media, CORE is encouraging individuals to “LiVE: 8” and end the wait by signing up to become an organ and tissue donor.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7253051-center-for-organ-recovery-and-education-launches-live-8/
Las familias se han transmitido de generación en generación los remedios caseros que han ayudado a que sus seres queridos se sientan atendidos, incluso durante esas etapas de congestión nasal y estornudos. Contar con un tazón de la famosa sopa de la abuela, o el cocimiento especial de la tía para curarse, contribuyen a que el cuerpo sane y a tranquilizar la mente. Recientemente, un grupo de madres blogueras hispanas revelaron los remedios a los que recurren sus familias para aliviar a sus seres queridos.
Para más, vaya a http://www.multivu.com/mnr/60905-kleenex-brand-tissue-favorite-family-home-remedies
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
Joerns Healthcare has launched the Dolphin Fluid Immersion Simulation® system that more effectively prevents and treats pressure-related injuries than other surfaces. This patented technology simulates the effect of floating in water for patients on hospital beds, stretchers, and in wheel chairs. The Dolphin technology continually adjusts to the patient’s body, promoting tissue perfusion and oxygenation, and minimizing injury related to compromised blood flow. The Dolphin is also proven to accelerate healing of advanced stage or multiple pressure ulcers, muscle flaps, skin grafts, burns and other wound conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58463-joerns-dolphin-fluid-immersion-simulation-system-pressure-related-injuries
Ethicon, Inc., a worldwide leader in surgical care, has announced its entrance into the barbed suture market with the launch of its new portfolio of STRATAFIX™ Knotless Tissue Control Devices, representing the next evolution in wound closure technology. With significantly more points of fixation than traditional sutures, STRATAFIX™ Devices give surgeons more consistent control over every pass (through the tissue), and combine the strength and security of interrupted closure with the efficiency of continuous closure.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58405-ethicon-launches-stratafix-knotless-tissue-control-devices
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Astellas Pharma Europe Ltd. today presented The Economist Innovation 2011 award for Bioscience to one of the world’s most influential biomedical engineers, Dr Robert Langer – the man responsible for founding the field of controlled-release drug delivery and tissue engineering.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellaspharma/52158/
The day when a surgeon can pull a new human vein “off the shelf” for use in life-saving vascular surgeries is now one step closer to reality. New research published in the current issue of the journal Science Translational Medicine demonstrates the efficacy of tissue-engineered vascular grafts (TEVGs) that are immediately available at the time of surgery and have decreased potential for infection, obstruction or clotting. The bioengineering method of producing veins reported in the newly-published research shows promise in both large and small diameter applications, such as for Coronary Artery Bypass Graft (CABG) surgery and for vascular access in hemodialysis.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/humacyte/48336/
Making it easier for consumers to take a “green step” at home, Kimberly-Clark today announced the introduction of the first toilet paper in the U.S. without the cardboard tube for use at home – Scott Naturals Tube-Free bath tissue. This innovative product eliminates the cardboard tube that has been the central fixture of rolled toilet paper for more than 100 years – a simple step with major potential to eliminate millions of pounds of material from the waste stream. Scotts Naturals Tube-Free bath tissue is currently being tested exclusively at select Walmart and Sam’s Club stores in the northeast U.S.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/scottnaturals/46945/
THINK: Flowers and fragrance—the ultimate Mother’s Day gift.
WHAT IT IS: A convenient, all-in-one gift kit for mom. This Mother’s Day, put your own personal touch on a classic gift with limited-edition Mother’s Day Fragrance Gift Kits. Each kit features a luxurious full-size fragrance, a $20 Saving Pass for 1800Flowers.com, a gift bag with tissue paper and a giftable pouch with a customizable “To-From” card. Priced at just $15.99, the affordable kits help you shower mom with flowers and fragrance with one easy purchase.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/coty/43854/
